Psychedelics biotech company Enveric Biosciences completed preclinical pharmacokinetic (PK) studies for its leading drug candidate EB-003 aimed at treating depression and anxiety without causing hallucinations. EB-003 is a neuroplastic and non-hallucinogenic N, N-Dimethyltryptamine (DMT) analog drug candidate., such as ataxia or hyperthermia.

Wondering how you can boost your brain health? A new study has found that sticking to one popular diet can help maintain a healthy brain and “decrease” the risk of cognitive decline over the years to come.

The focus on mental wellness at work has become increasingly urgent, especially in the context of remote work. The flexibility of remote work allows employees to design a workday that suits their needs and supports a healthy work-life balance. However, it also lacks the essential social support systems, commonly found in traditional office environments.

Sometimes it takes more than sheer will to get household jobs done or build good habits into your daily chores. I’m a licensed psychotherapist and know full well how the experiences that have shaped us over the course of a lifetime, including trauma, chronic pain, and anxiety can impact our capacity and motivation to do […]

Taking care of a dog is a big responsibility, no doubt. And yes, sometimes it can even be a little frustrating. My six-month-old Shih-Tzu, Alfie, is still convinced that Balenciaga 3XLs are the ultimate chew toy. (He’s on a real shoelace kick, so I get it.) But most every dog owner would agree that the […]

In the new study, co-author Laura Pritschet, a PhD student, and her team determined that along with a rise in estrogen and progesterone, the gray matter in the pregnant woman’s brain deteriorated over the course of her gestation, starting as early as the ninth week.1 Neuroanatomical changes observed over the course of a human pregnancy. […]

Enveric Biosciences Inc, a biotechnology company specializing in neuroplastogen therapeutics for mental health conditions, has entered into a licensing agreement with MycoMedica Life Sciences. Enveric will out-license its EVM201 program, including the drug candidate EB-002 (formerly EB-373), to MycoMedica. The partnership is set to bring forward the development of EB-002, a synthetic prodrug of psilocin for […]

The biotech will concentrate on its “trip-free” compound, especially following recent FDA concerns on psychedelic trial designs. Enveric Biosciences (NASDAQ: ENVB) agreed to license one of its experimental psychedelic drug candidates to MycoMedica Life Sciences in a deal worth as much as $62 million, as the biotech company keeps its eye on its non-hallucinogenic treatments.

Many biotech startups decide to operate in what is known as “stealth mode”. Here, they are almost invisible to the outside world, able to look inward and avoid the distractions and tribulations that can potentially arise from being in the public eye. But what exactly is stealth mode and what benefits does it offer young […]

Enveric Biosciences ENVB recently announced that research highlighting the Company’s lead compound, EB-003, is being presented at the 7th Neuropsychiatric Drug Summit. EB-003 is a promising neuroplastogenic and non-hallucinogenic N, N-Dimethyltryptamine (DMT) analog drug candidate that elicited beneficial outcomes in preclinical models of anxiety and depression. The conference is being held at the Hilton Boston […]